On the other hand, in advanced stages, the therapeutic strategy could involve a TLR4-antagonist, because, generally, a high inflammatory response increases the levels of TLR4, which is responsible for harmful events in the inflammatory immunosuppressive microenvironment, with a subsequent tumor-promoting role in HPV-related cervical cancer. This evidence concerns the gene TLR4 and cervical carcinoma.